Our Research

Engineered with experts at West Texas A&M University, our proprietary AFLPCO™ and AFL PLASMA® technologies lead the way in next-generation ionization. Lab-tested to destroy 99.997% of harmful pollutants—including bacteria, viruses, mould, PM2.5, allergens, odours, and VOCs—they purify both the air you breathe and the surfaces you touch.

How it works

ALFPCO® TECHNOLOGY

UVC lamp targets and neutralizes airborne germs as they pass through
AFLPCO™ metal catalyst reacts with UV light to release purifying negative ions
Negative ions diffuse and destroy pathogens by deactivating DNA.
Dead pathogens convert into water and carbon dioxide.

AFL PLASMA® TECHNOLOGY

Plasma electrodes split water molecules into powerful H⁺ and OH⁻ ions
Ions surround and break down allergens, dust, pollen, and pollutants
Impurities bond with ions, gain weight, and fall from the air
After purification, H⁺ and OH⁻ ions safely recombine to form pure water molecules

Efficacy Test Results of ALFPCO™ & AFL PLASMA™

Experimental procedure: Bacterial samples were spread on agar plates. One plate was exposed to ionized air generated via ALFPCO™ & AFL PLASMA™ while the other was exposed to regular air. The rate of bacterial decay were compared and analyzed.
Specimen Health Issues Associated Exposure Time to ALFPCO™ & AFL PLASMA™ (min.) Elimination Rate (%)
Enterococcus faecium Pneumonia, infection of the urinary tract, soft tissues, and blood 60 99%
Staphylococcus aureus (MRSA) Pneumonia, food poisoning, toxic shock syndrome, and infection of the skin, blood, and bones 30 96.24%
Escherichia coli Diarrhea, vomiting, fever, stomach cramps, and kidney failure 60 99.23%
Clostridium difficile Diarrhea, fever, severe cramping, intestinal inflammation, and sepsis 30 86.87%
HCoV-229E Pneumonia, Bronchiolitis, fever, cough, aches and pains, and diarrhoea 60 99.41%
MERS-CoV Pneumonia, Shortness of breath, Gastrointestinal infection, Nausea & vomitting 60 / 240 99.78% / 99.997%

References

1. Agudelo Higuita NI, Huycke MM. Enterococcal Disease, Epidemiology, and Implications for Treatment. 2014 Feb 4. In: Gilmore MS, Clewell DB, Ike Y, et al., editors. Enterococci: From Commensals to Leading Causes of Drug Resistant Infection [Internet]. Boston: Massachusetts Eye and Ear Infirmary; 2014-.
Available at: https://www.ncbi.nlm.nih.gov/books/NBK190429


2. Smith, D. S., Lindholm-Levy, P., Huitt, G. A., Heifets, L. B., & Cook, J. L. (2000). Mycobacterium terrae: Case Reports, Literature Review, and In Vitro Antibiotic Susceptibility Testing. Clinical Infectious Diseases, 30(3), 444–453.
Available at: https://doi.org/10.1086/313693


3. Rainard, P., Foucras, G., Fitzgerald, J.R., Watts, J. L., Koop, G., & Middleton, J. R. (2017). Knowledge gaps and research priorities in Staphylococcus aureusmastitis control. Transboundary and Emerging Diseases, 65, 149–165.
Available at: https://doi.org/10.1111/tbed.12698


4. Rock, C., & Rivera, B. (2014). Water quality, E. coli and your health. Coorperative Ext.


5. Czepiel, J., Dróżdż, M., Pituch, H., Kuijper, E. J., Perucki, W., Mielimonka, A., Goldman, S., Wultańska, D., Garlicki, A., & Biesiada, G. (2019). Clostridium difficile infection: review. European Journal of Clinical Microbiology & Infectious Diseases, 38(7), 1211–1221.

Available at: https://doi.org/10.1007/s10096-019-03539-6